Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 201.30K | 140.80K | 77.90K | 94.30K | 110.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.30K | 140.80K | 77.90K | 94.30K | 110.30K |
| Cost of Revenue | 12.90K | 24.80K | 36.80K | 55.90K | 74.60K |
| Gross Profit | 188.40K | 116.10K | 41.20K | 38.50K | 35.80K |
| SG&A Expenses | 3.46M | 4.07M | 4.68M | 5.74M | 6.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -420.80K | -346.60K | -269.30K | -708.00K | -1.14M |
| Total Operating Expenses | 6.55M | 7.55M | 8.53M | 9.51M | 10.43M |
| Operating Income | -6.35M | -7.41M | -8.45M | -9.41M | -10.32M |
| Income Before Tax | -6.30M | -7.39M | -8.46M | -8.85M | -9.21M |
| Income Tax Expenses | -- | -33.90K | -68.20K | -68.20K | -68.20K |
| Earnings from Continuing Operations | -6.30 | -7.35 | -8.39 | -8.78 | -9.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.30M | -7.35M | -8.39M | -8.78M | -9.14M |
| EBIT | -6.35M | -7.41M | -8.45M | -9.41M | -10.32M |
| EBITDA | -5.98M | -7.03M | -8.09M | -8.95M | -9.77M |
| EPS Basic | -0.15 | -0.20 | -0.26 | -0.31 | -0.36 |
| Normalized Basic EPS | -0.10 | -0.13 | -0.16 | -0.21 | -0.26 |
| EPS Diluted | -0.15 | -0.20 | -0.26 | -0.31 | -0.36 |
| Normalized Diluted EPS | -0.10 | -0.13 | -0.16 | -0.21 | -0.26 |
| Average Basic Shares Outstanding | 165.71M | 153.14M | 140.56M | 121.13M | 102.29M |
| Average Diluted Shares Outstanding | 165.71M | 153.14M | 140.56M | 121.13M | 102.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |